Voxly Vision
Three Things You'll Learn Reading This Article
- How does the ASA's AI decide an ad is promoting a prescription-only medicine, even when the medicine is never named?
- Why can an ad that looks compliant on its own still break the rules once you follow the click to the landing page?
- When does a "coming soon" teaser or waitlist count as advertising, and why does the timing matter?
The UK advertising regulator now processes tens of millions of ads a year with the help of AI. On 7 October 2026 it published six rulings, and five concerned online pharmacies advertising weight-loss treatments. Read together, they show clearly what the regulator looks for, and how a good sign-off process can catch the same things first.
The rulings say these cases were identified through complaints and intelligence gathered by the ASA, as part of a wider project on prescription-only medicines (POMs) for weight loss. The ASA has said separately that its AI-based Active Ad Monitoring system supports that project. The rule at the centre is short: CAP Code rule 12.12 says prescription-only medicines must not be advertised to the public.
What the ASA's AI actually does
The ASA describes Active Ad Monitoring as an AI-powered system, built in-house, that captures paid social, search and website ads as well as influencer content. AI models pick out ads relevant to a topic and flag those that may break the rules. ASA experts then review what is flagged and decide whether action is needed. In 2025 the system processed more than 60 million ads, and by the end of that year proactive work made up 45% of the ASA's regulatory resource, up from 5% in 2012.
On weight-loss medicines, the ASA says it captured and assessed tens of thousands of ads from high-priority advertisers and found around 900 likely to breach the rules, from 38 of the 44 advertisers monitored.
Lesson: the regulator's first pass is now automated and topic-led, so a whole category can be swept at once.
It reads signals, not just names
Juniper's Google search ad named no medicine. It said "Weight Loss Medication", "No GP or pharmacy visits, just a quick online consultation" and "Lose Up To 23% Of Your Body Weight. Reduce Cravings & Regulate Appetite", alongside prices. The ASA drew on its April 2026 consumer research, which found that claims about cravings and appetite, and images of injector pens, strongly signal a prescription-only medicine. Taken together, it ruled, the ad promoted a POM to the public.
The Care Pharmacy's search ad showed a grey, pen-shaped product with a dosage window next to its branded box. No drug name was needed: the ASA considered that many consumers would read it as a weight-loss injection pen. MedExpress's Facebook ad said its treatment "helps silence food noise" and "Controls your cravings". The ASA noted that claims about appetite, cravings and feeling fuller for longer are permitted only for prescription-only weight-loss medicines, not over-the-counter products.
Lesson: check what an ad implies as a whole, images included, not just a list of banned words.
It follows the click
In all three cases the journey ended at named POMs. The Care Pharmacy and MedExpress ads led through an age gate to landing pages showing branded injection pens. Juniper argued that several information-gathering pages acted as a buffer before any branded content. The ASA disagreed: drawing on advice from the MHRA, it found the ad guided people along "a discrete path" to a named POM, even though the message was spread across several pages. The ASA treats a landing page reached from a paid ad as akin to a homepage under the MHRA's Blue Guide.
Credit where it is due: The Care Pharmacy told the ASA it removed the ad, is auditing its paid advertising and linked pages, and will bring in a stricter approval process.
Lesson: sign-off has to cover the whole journey, from ad to age gate to landing page, not just the creative.
Pre-launch buzz is still advertising
Pharmacy Online and Simple Online Pharmacy both ran "coming soon" ads for oral weight-loss tablets in early June 2026, with lines such as "NO NEEDLE. COMING SOON." and "The same medication. The same mechanism. But a tablet". The first oral GLP-1 tablet for weight management was not licensed in the UK until 11 June. The ASA ruled that the earlier ads made medicinal claims for unlicensed products (rules 12.1 and 12.11), and that later ads, once the tablet was a POM, promoted it to the public.
Simple Online Pharmacy has since introduced a two-stage approval process for weight-management advertising, updated its compliance checklists and given its marketing team refresher training.
Lesson: waitlists and early-access offers are ads, and their timing against a product's legal status matters.
What to check before your next campaign
- Does any image, word or claim imply a regulated product, even one you never name?
- Where does the click go: age gate, landing page and the pages after it?
- Has the product's licence or legal status changed since the brief was written?
- Did anything go live outside normal review, such as an agency-built pop-up?
- Do founder or staff posts promote the business? If so, treat them as ads.
- Is there a record of who signed off each asset, and when?
Getting sign-off right at speed
The regulator now pairs AI scale with human judgement: its AI flags, its experts decide. Ad compliance AI lets brands run the same model before launch, so problems can be caught before an ad goes live.
Voxly Vision checks images, video and copy against regulations and brand guidelines, and flags issues for a person to review. Diageo uses it and cut ad sign-off from more than three days to about an hour, with review time per asset down from 5 to 10 minutes to about 60 seconds. A person still makes the final call.
